Fig. 2
From: Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo
serpina3n delays the onset and attenuates the severity of the disease in EAE. a Fifty μg of serpina3n was given at day 7 post EAE induction, and a clinical evaluation followed for 36 days. Mice treated with serpina3n started to show EAE symptoms later than the control group; the severity of the disease was lower in the treated group when compared to the untreated control group. b The graph shows SOS of “A”. There is no significant difference between the treated and untreated group because the effect of serpina3n was lost after day 20 post EAE induction. c Fifty μg of serpina3n was administered IV to the entire experimental group at once when the first mouse in the group showed EAE symptoms. The effect of serpina3n was again lost after day 20/21. d There is no difference in SOS in “C” between the treated and untreated group